Biotech: Page 74
-
Getty Images
Moderna sued for allegedly infringing patents tied to COVID-19 vaccine
Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies.
By Ned Pagliarulo • Feb. 28, 2022 -
Biohaven stocks up on experimental drugs with new acquisition, licensing deal
Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.
By Jacob Bell • Feb. 25, 2022 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna bets on booster demand, advancing new 'bivalent' COVID-19 shot
The biotech will start trials in the U.S. and U.K. of a vaccine that targets both the original coronavirus strain and the omicron variant.
By Jonathan Gardner • Feb. 24, 2022 -
Amicus' SPAC deal unravels, leading to layoffs and cost cuts
The biotech is calling off plans to spin out its gene therapy business via a merger with a blank check company, citing unfavorable market conditions and a "challenging environment."
By Kristin Jensen • Feb. 24, 2022 -
Kodiak crashes on negative trial results for would-be Eylea competitor
Data from a Phase 3 trial showed Kodiak's experimental treatment didn't match up to Eylea in wet AMD, spurring questions from analysts about its potential.
By Kristin Jensen • Feb. 23, 2022 -
Permission granted by Spark Therapeutics
Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down
Jeffrey Marrazzo has led Spark since its founding in 2013, through the historic FDA approval of Luxturna and the company's $4.3 billion buyout by Roche.
By Ned Pagliarulo • Feb. 23, 2022 -
Maddie Meyer via Getty Images
Moderna, on the heels of pharma rivals, cleared to advance RSV vaccine
The race to launch the first preventive shot for the common respiratory illness now has four entrants in Phase 3 testing, although bigger drugmakers lead the mRNA specialist.
By Jonathan Gardner • Feb. 22, 2022 -
Permission granted by Adagio Therapeutics
Adagio pledges to press forward with COVID drug as CEO to resign
Tillman Gerngross, who founded Adagio and helped it raise $800 million on the promise of finding better antibody medicines for COVID-19, will step down amid confusion over how well its lead treatment works against omicron.
By Ned Pagliarulo • Feb. 22, 2022 -
Getty Images
Sponsored by SGSMeso Scale Discovery (MSD): An immunoassay platform with varied applications in the biopharmaceutical industry
Learn how MSD is a one stop immunoassay platform that could be a time- and cost-effective alternative to the regularly used bio-molecule detection technologies in the laboratory.
By Riya Binil, Scientific Leader, Cell Biology • Feb. 22, 2022 -
Jonathan Gardner/BioPharma Dive
With drug approval, Agios hits first key milestone after major shakeup
The biotech, which recently narrowed its research focus to rare blood disorders, is now cleared by the FDA to start selling the first medicine for a rare form of anemia.
By Jacob Bell • Feb. 18, 2022 -
Yumanity cutting 60% of employees as it mulls possible sale
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.
By Jacob Bell • Feb. 17, 2022 -
Getty Images
J&J to explore RNA reprogramming with Remix research deal
The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.
By Kristin Jensen • Feb. 17, 2022 -
Permission granted by Third Harmonic
Third Harmonic, led by former Audentes CEO, launches with $155M in funding
Natalie Holles was named as head of the Atlas-backed startup last year after leaving gene therapy developer Audentes following its acquisition by Astellas.
By Ned Pagliarulo • Feb. 16, 2022 -
Getty Images
Star Therapeutics emerges with plans to treat rare diseases through a solar system of drug companies
Star Therapeutics has an unusual hub-and-spoke model that it believes will make rare disease research more efficient. Its first company was unveiled Wednesday, and CEO Adam Rosenthal says another is waiting in the wings.
By Jacob Bell • Feb. 16, 2022 -
Kena Betancur via Getty Images
How the biotech downturn is already affecting drug startups
At an industry conference Monday, a group of venture investors noted changes in how long biotechs are taking to raise money, and a shifting outlook among investors who specialize in shepherding young companies to an IPO.
By Ben Fidler • Feb. 14, 2022 -
Permission granted by Mateusz Bartkowiak (QIAGEN)
Sponsored by QIAGENThe key to target and biomarker discovery
The secret's in the biological context: how to accelerate biological discovery and validation.
Feb. 14, 2022 -
Getty Images
ProQR eye drug comes up short in key study, surprising company and investors
The biotech's treatment did not improve vision in the Phase 2/3 trial, a significant setback that sent shares down by 75%.
By Ned Pagliarulo • Feb. 11, 2022 -
Seagen shares sink as sales outlook of cancer drug disappoints
The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.
By Jacob Bell • Feb. 10, 2022 -
Editas' executive shake-up continues
Shares of the gene editing biotech slumped Tuesday on news that chief medical officer Lisa Michaels had joined a growing list of executive departures.
By Jacob Bell • Feb. 8, 2022 -
Courtesy of Business Wire
Al Sandrock, former top Biogen scientist, to join drug discovery startup's board
Sandrock's appointment to Verge Genomics' board of directors follows about a week after the executive took up a similar post with Voyager Therapeutics.
By Ned Pagliarulo • Feb. 8, 2022 -
Spencer Platt via Getty Images
Deep Dive // Emerging biotech
‘The music stopped’: Biotech rout leaves drug startups grounded as demand slumps for IPOs
For the first time in years, biotechs no longer had an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.
By Ben Fidler • Feb. 7, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
More federal regulators investigating Biogen Alzheimer's drug
In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.
By Jacob Bell • Feb. 4, 2022 -
Courtesy of Intellia Therapeutics
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.
By Ned Pagliarulo • Feb. 3, 2022 -
Permission granted by Biogen
Biogen's Alzheimer's drug sales remain slow as company warns of further cost cuts
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.
By Jacob Bell • Updated Feb. 3, 2022 -
Courtesy of Sarepta
Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods
The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.
By Ned Pagliarulo • Feb. 1, 2022
Previous
